On July 5, 2012, Alexza Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food & Drug Administration (the "FDA") has accepted the Company's resubmitted ADASUVE New Drug Application as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act goal date of December 21, 2012. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

(d) Exhibits.

Exhibit
Number                                    Description

99.1         Press Release titled "Alexza Announces Adasuve™ (Staccato® Loxapine)
             PDUFA Goal Date of December 21, 2012," dated July 5, 2012.